14. SEGMENTS

3 Months Ended

Jun. 30, 2014

Segment Reporting [Abstract]

14. SEGMENTS

We operate our businesses principally through two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic business activities. Our reportable segments have been determined based on the nature of the potential products being developed. ESI did not have any operations in the three months ended June 30, 2013.

Aethlon’s revenue is generated primarily from government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead to the ESI segment.

The following tables set forth certain information regarding our segments and other operations that conforms to the consolidated balance sheet and statement of operations presented in this Report:

	Three Months Ended June 30,
	2014			2013
Revenues:
Aethlon	$	51,296		$	195,596
ESI		–			–
Total Revenues	$	51,296		$	195,596
Operating Losses:
Aethlon	$	(930,252	)	$	(783,798	)
ESI		(241,756	)		–
Total Operating Loss	$	(1,172,008	)	$	(783,798	)
Net Losses:
Aethlon	$	(3,462,536	)	$	(303,498	)
ESI		(241,756	)		–
Net Loss Before Non-Controlling Interests	$	(3,704,292	)	$	(303,498	)
Cash:
Aethlon	$	45,704		$	31,653
ESI		761,626			–
Total Cash	$	807,330		$	31,653
Total Assets:
Aethlon	$	294,662		$	195,243
ESI		849,786			–
Total Assets	$	1,144,448		$	195,243
Capital Expenditures:
Aethlon	$	–		$	–
ESI		–			–
Capital Expenditures	$	–		$	–
Depreciation and Amortization:
Aethlon	$	4,442		$	2,436
ESI		4,896			–
Total Depreciation and Amortization	$	9,338		$	2,436
Interest Expense:
Aethlon	$	(35,626	)	$	106,096
ESI		–			–
Total Interest Expense	$	(35,626	)	$	106,096